Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus T

Indication
Triple Negative Breast Cancer

Other upcoming events for GILD

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination Wit
Phase 3 ReadoutPhase 3 Topline: An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and E
Patent ExpiryPatent/Exclusivity Expiry: YEZTUGO
Patent ExpiryPatent/Exclusivity Expiry: SUNLENCA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus T — GILD Phase 3 Readout | BioSniper